Company intelligence / Profile preview

Nereus Pharmaceuticals

San Diego, California, United Statesen.wikipedia.org ↗

Ownership: Private
Development stage: Phase 2

Overview

Nereus developed a pipeline of small molecule therapeutics derived from marine microorganisms. Its lead compounds included plinabulin (NPI‑2358), a vascular disrupting agent for solid tumors and HER2-negative breast cancer that later advanced to Phase 3 under BeyondSpring; salinosporamide A (NPI‑0052), a proteasome inhibitor for multiple myeloma and other cancers; and NPI‑1342/NPI‑1302a‑3 targeting the NF-kappa B pathway for oncology and inflammation. The company was acquired by Triphase Research & Development in 2012. Several programs were discontinued or outlicensed after acquisition.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculePeptides
Industry: Biotech

Partnerships

University of California San DiegoBeyondSpring Pharmaceuticals

Beyond the preview

Go deeper on Nereus Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nereus Pharmaceuticals.

Explore the full profile